AbstractKaposi's Sarcoma Herpesvirus (KSHV) is the causative agent of several human diseases. There are no cures for KSHV infection. KSHV establishes biphasic lifelong infections. During the lytic phase, new genomes are replicated by seven viral DNA replication proteins. The processivity factor's (PF‐8) functions to tether DNA polymerase to DNA, so new viral genomes are efficiently synthesized. PF‐8 self‐associates, interacts with KSHV DNA replication proteins and the viral DNA. Inhibition of viral DNA replication would diminish the infection within a host and reduce transmission to new individuals. In this review we summarize PF‐8 molecular and structural studies, detail the essential protein‐protein and nucleic acid interactions needed for efficient lytic DNA replication, identify future areas for investigation and propose PF‐8 as a promising antiviral target. Additionally, we discuss similarities that the processivity factor from Epstein‐Barr virus shares with PF‐8, which could promote a pan‐herpesvirus antiviral therapeutic targeting strategy.